Daraxonrasib Doubles Median Survival in Phase 3 Trial — A Rare Breakthrough for Metastatic Pancreatic Cancer

Phase 3 results presented at ASCO show daraxonrasib, an oral RAS-pathway inhibitor, nearly doubled median overall survival to 13.2 months versus 6.7 months with standard chemotherapy in ~500 patients with previ...



























